|
|
|
Yale Trial Aims at Ovarian Cancer
|
Business New Haven
1/6/2003
By: BNH
|
NEW HAVEN - Yale School of Medicine researchers are testing a new treatment for women with recurrent ovarian cancer, the fourth-leading cause of cancer-related deaths among American women, affecting one in 100 females.
The women will be administered phenoxodiol, a drug known to unblock death receptors vital to the destruction of cancer cells. The Phase II clinical trial is taking place at sites worldwide; Yale hosts the only participating U.S. site. The trial is intended to determine the efficacy of a drug already proven non-toxic in Phase I.
“This is a completely new approach in the treatment of ovarian cancer,” says Gil Mor, M.D., associate professor of obstetrics and gynecology, who will lead the Yale trial with colleague Thomas Rutherford, M.D., associate professor of gynecologic oncology. “We are finding that phenoxodiol is able to induce cell death in ovarian cancer cells that proved to be resistant to other drugs, including those presently in use for ovarian cancer.”
About 40 women will be enrolled in the trial initially.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
